Adolor cuts 30 jobs on low Entereg sales; Amgen chooses Novartis exec as CFO;

@FiercePharma: Sanofi ops shift threatens up to 600 jobs. News | Follow @FiercePharma

> Exton, PA-based Adolor is cutting 30 jobs, or about a third of its workforce, as it attempts to reduce cash burn levels. The developer had 114 employees at the end of 2009. Report

> Amgen has tapped Jonathan Peacock, a top finance executive at Novartis, as its new CFO. Report

> Roche's top-seller Avastin didn't slow breast tumors in new studies as much as in earlier data used to win approval, according to U.S. regulators weighing whether to permit continued sales for this use. Report

> K-V Pharmaceutical named Chief Accounting Officer Thomas McHugh as its new CFO, replacing Stephen Stamp after three months. Report

> Cubist Pharmaceuticals posted quarterly results that beat market estimates, driven by strong U.S. sales of its drug Cubicin. Report

> Sepracor, best known for its Lunesta sleep aid, will be renamed Sunovion Pharmaceuticals in the U.S. by the end of the year. Report

> Somaxon Pharmaceuticals stock rose on news that it had inked a deal for Publicis Touchpoint to provide contract sales reps for its insomnia drug Silenor. Report

> Apicore said its API manufacturing plant in Somerset, N.J., successfully completed an FDA inspection earlier this week. Apicore release

Biotech News

 @FierceBiotech: Arena shares surge on new round of promising lorcaserin data. Story | Follow @FierceBiotech

 @JohnCFierce: Today's Vivus vote helps explain why biotechs are having a tough time finding pharma partners for obesity drugs. It's a minefield. Follow @JohnCFierce

> Biotech takes top spot in Q2 VC investment. Story

> Vernalis Parkinson's drug sinks on tox issues. Item

> CSL to expand, create 333 jobs. Article

> Expert panel not convinced by Vivus' Qnexa. News

> Galapagos inks drug discovery pact. Report

And Finally... The largest study to correlate genetics with response to cancer drugs released its first results. Report

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.